Rifabiz 200 Tablet

Overview: Rifabiz 200 Tablet contains rifaximin, a broad spectrum antibiotic that treats traveller's diarrhoea (loose stools and cramps caused by contaminated food), hepatic encephalopathy (severe liver disease affecting the brain) and irritable bowel syndrome (chronic bloating, diarrhoea and stomach pain). It works by stopping the growth of diarrhoea-causing bacteria, altering the gut biome and lowering the ammonia-producing microorganisms present in the gut.

Dosage: Rifabiz 200 Tablet should be taken as advised by your doctor. The recommended dose for Traveler's Diarrhoea is 200 mg 3 times a day for three days. For Hepatic Encephalopathy, 550 mg twice a day. And for Irritable Bowel Syndrome, 550 mg orally three times a day. This medication may be taken with or without food. It is advised to consume the tablet whole with water and to refrain from crushing or chewing it.

Side effects: The common side effects of Rifabiz 200 Tablet include headache, nausea, dizziness, stomach pain, peripheral oedema, excessive fatigue, muscle stiffness and joint pain. They typically last for a short period and usually go away on their own. Contact your healthcare provider if the problems persist or worsen.

Safety advice: Rifabiz 200 Tablet may be contraindicated (unsafe) for people experiencing fever or bloody diarrhoea (blood in stool); and those with a history of colitis (inflamed colon), renal dysfunction, liver disease and hypersensitivity to rifaximin. Always inform your doctor of any health conditions you might have. Generally, this drug is considered safe for most people.

General overview: Rifabiz 200 Tablet contains rifaximin, a broad-spectrum antibiotic effective against aerobic and anaerobic bacteria. It lowers bacterial virulence and pathogenicity in the digestive tract to treat various bacterial infections and the following symptoms. It also stops the ammonia-producing bacteria from growing, which prevents a disorder called hepatic encephalopathy from worsening.

Mechanism of actions: Rifaximin works by inhibiting RNA synthesis in bacteria that are vulnerable to its effects. This inhibition is achieved through the binding of the drug to the beta-subunit of bacterial DNA-dependent RNA polymerase enzyme, thereby disrupting the process of translocation and ultimately leading to the cessation of transcription.

<p><a href="https://medlineplus.gov/druginfo/meds/a604027.html">Rifaximin (medlineplus.gov)</a></p> <p><a href="https://www.ncbi.nlm.nih.gov/books/NBK562329/">Rifaximin: a general overview (www.ncbi.nlm.nih.gov)</a></p> <p><a href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021361s023lbl.pdf">Rifaximin tablets for oral use (accessdata.fda.gov)</a></p>